Skip Navigation
Skip to contents

Urogenit Tract Infect : Urogenital Tract Infection

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Antibiotic resistance"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review Articles
Molecular Mechanisms of Antibiotic Resistance in Uropathogenic Escherichia coli: A Narrative Review
Nakjun Choi, Dong Uk Kim, Eun-Jin Lee
Urogenit Tract Infect 2025;20(2):96-106.   Published online August 31, 2025
DOI: https://doi.org/10.14777/uti.2550018009
AbstractAbstract PDFPubReader
Urinary tract infections (UTIs) are among the most prevalent bacterial infections worldwide, with uropathogenic Escherichia coli (UPEC) serving as the primary causative agent. Although antibiotic therapy remains the standard of care for UTI treatment, the increasing prevalence of antimicrobial resistance has substantially reduced the effectiveness of commonly prescribed antibiotics. Resistance to trimethoprim-sulfamethoxazole (TMP-SMX), β-lactams, and fluoroquinolones is particularly concerning, as these agents constitute the principal therapeutic options for UTIs. This review examines the molecular mechanisms underlying UPEC resistance to these three classes of antibiotics, including target site modifications, efflux pump overexpression, porin regulation, and enzymatic degradation. Furthermore, it explores how these resistance determinants contribute to the development of multidrug-resistant (MDR) UPEC strains, which demonstrate cross-resistance to multiple antibiotics and present significant challenges for clinical management. Novel therapeutic strategies, such as efflux pump inhibitors, bacteriophage therapy, and genomic-guided precision medicine, are under investigation as potential solutions to address the growing global burden of MDR UPEC, alongside alternative non-antibiotic treatments. This review aims to provide a comprehensive overview of the genetic and regulatory pathways driving antibiotic resistance in UPEC, offering insights that may guide the development of effective treatment strategies and help mitigate the ongoing spread of antimicrobial resistance.

Citations

Citations to this article as recorded by  
  • Editorial for Urogenital Tract Infection (UTI) 2025 Vol. 20 No. 2 – Highlights of This Issue’s Papers and the UTI Editors’ Pick
    Koo Han Yoo
    Urogenital Tract Infection.2025; 20(2): 55.     CrossRef
  • 332 View
  • 18 Download
  • 1 Crossref
Close layer
Beta-Lactamase-Mediated Antibiotic Resistance in Urinary Tract Infections: Mechanisms and Therapeutic Strategies
Fanglin Shao, Dengxiong Li, Jie Wang, Zhouting Tuo, Zhipeng Wang, Wuran Wei, Ruicheng Wu, Dechao Feng
Urogenit Tract Infect 2025;20(2):67-81.   Published online August 31, 2025
DOI: https://doi.org/10.14777/uti.2550012006
AbstractAbstract PDFPubReader
Urinary tract infections (UTIs) are among the most prevalent bacterial infections globally, and are primarily caused by Escherichia and Klebsiella. The overprescription and inappropriate use of antibiotics have accelerated the emergence of multidrug-resistant bacteria. Beta-lactamases play a critical role in mediating antibiotic resistance in UTIs. These enzymes promote bacterial resistance through multiple mechanisms, including gene mutation, plasmid-mediated horizontal gene transfer, and the involvement of integrons. Comprehensive knowledge of the ways in which beta-lactamases contribute to resistance in UTIs is essential for improving treatment strategies. Advances in detection technologies, such as gene sequencing and mass spectrometry, have greatly enhanced the ability to monitor and predict bacterial resistance. Current therapeutic strategies include the application of beta-lactamase inhibitors, the development of novel antibiotics, and alternative treatments that have shown efficacy against beta-lactamase-mediated antibiotic resistance. This paper reviews the mechanisms of beta-lactamase-mediated resistance in UTIs and provides an in-depth overview of several detection methods and therapeutic approaches.

Citations

Citations to this article as recorded by  
  • Editorial for Urogenital Tract Infection (UTI) 2025 Vol. 20 No. 2 – Highlights of This Issue’s Papers and the UTI Editors’ Pick
    Koo Han Yoo
    Urogenital Tract Infection.2025; 20(2): 55.     CrossRef
  • 226 View
  • 12 Download
  • 1 Crossref
Close layer
Original Article
Fournier’s Gangrene: A 10-Year Clinical Experience at a Tertiary Academic Medical Center
Woo Seop Seong, Byeong Jin Kang, A Reum Kim, Kyung Hwan Kim, Hong Koo Ha
Urogenit Tract Infect 2023;18(2):64-69.   Published online August 31, 2023
DOI: https://doi.org/10.14777/uti.2023.18.2.64
AbstractAbstract PDFPubReaderePub
Purpose: This retrospective study examined the factors influencing clinical outcomes and mortality in patients with Fournier's Gangrene (FG). The medical history, diagnostic procedures, treatment approaches, complications, and mortality factors associated with FG were analyzed.
Materials and Methods: This study retrospectively analyzed the medical records of 40 patients with FG treated over 10 years. The collected data included the patient demographics, comorbidities, vital signs, laboratory tests, Fournier’s Gangrene Severity Index (FGSI) scores, wound swab culture results, treatment approaches, and length of hospitalization.
Results: Among the patients with FG, diabetes mellitus and hypertension were the most common comorbidities. The hemodialysis dependence has been identified as a significant risk factor of mortality. In addition, septic shock and an FGSI >9 were associated with increased mortality. Escherichia coli was the most prevalent bacterium in wound swab cultures, and the presence of antibiotic-resistant bacteria was significantly higher in the non-survivors. Treatment involved broad-spectrum antibiotics, emergency surgical debridement, and subsequent adjustments based on culture results.
Conclusions: Early diagnosis and prompt initiation of treatment are essential for improving the outcomes of patients with FG. Hemodialysis dependency, septic shock, FGSI scores, and the presence of antibiotic-resistant bacteria are important factors associated with mortality in patients with FG. Further research will be needed to validate these findings and explore adjunctive therapies to enhance the patient outcomes and improve FG management.

Citations

Citations to this article as recorded by  
  • Prognostic factors and clinical outcomes in Fournier’s Gangrene: a retrospective study of 35 patients
    Han Bee Hong, Jeong Woo Lee, Chan Hee Park
    BMC Infectious Diseases.2024;[Epub]     CrossRef
  • 1,333 View
  • 14 Download
  • 1 Crossref
Close layer

Urogenit Tract Infect : Urogenital Tract Infection
Close layer
TOP